Eisai to sell clinical diagnostics supply business

By Gareth Macdonald

- Last updated on GMT

Eisai to sell clinical diagnostics supply business
Eisai will sell its clinical diagnostics business – EIDIA Co. Ltd - to Sekisui Chemical for JPY 22.4bn ($183m).

The deal – which is expected to complete by the end of December – will see Sekisui take control of EIDIA’s diagnostic reagents, diagnostic and laboratory equipment businesses. Eisai will retain all biomarker-related development programmes.

EIDIA has worked with Sekisui’s subsidiary – Sekisui Medical – on the development, production and sale of clinical diagnostics reagents to the pharmaceutical industry since 2007.

The firm employs 157 people all of whom are expected to transfer to Sekisui when the deal completes.

Eisai said the sale followed its decision to focus management resources on the pharmaceutical business, specifically on the development of oncology and neurology   

The Tokyo-headquartered drugmaker said its continuing research in the field of diagnostics will be concentrated on its precision and personalized medicine development programmes.

Pipeline focus

Eisai's decision to refocus on cancer and central nervous system (CNS) drugs has already seen it reorganise this year.

In April​ the Japanese company said it planned to reduce the size of its US workforce by 25%.

At the time CVEO, Yuji Matsue, said the cutbacks would allow it to "redeploy our resources to support the development of our proprioty late stage compounds and our current product portfolio​."

And in July Eisai agreed to sell its manufacturing campus in Research Triangle Park in the US to Biogen.

Related news

Related products

show more

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Product Brochure

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Related suppliers

Follow us

Products

View more

Webinars